

**ASX Announcement | 13 November 2023  
Vioneering Technologies (ASX:VTI)**

**Notice given under Section 708A(5)(e) of the Corporations Act**

**Vioneering Technologies, Inc. (ASX: VTI)** ('**Vioneering**' or 'the **Company**'), producer of the NaturalVue® Multifocal 1 Day Contact Lenses, gives this notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) (as modified by ASIC Class Order 14/827 (**Class Order**)).

Vioneering has issued 7,954,545 CHESS Depositary Interests (**CDIs**) today as a result of the conversion of 1,120,000 convertible notes and 845,071 shares of Class A common stock on Friday, 10 November 2023 (AEDT) under a placement to the non-executive directors announced on 10 October 2023 and approved by stockholders at a special meeting of the Company on 2 November 2023.

On 27 May 2020, ASIC granted Vioneering a modification of section 708A(5)(d) of the Corporations Act to address certain technical financial reporting relief granted to Vioneering by ASIC. Accordingly, Vioneering is relying on section 708A(5) on the basis that section 708A(5)(d) is modified by ASIC Corporations (Disregarding Technical Relief) Instrument 2016/73 and ASIC Instrument [20-0518] as applicable) and gives notice that it has issued the CDIs and shares without disclosure to investors under Part 6D.2 of the Corporations Act.

As at the date of this notice, Vioneering:

1. has complied with section 601CK (as that provision applies to Vioneering) and sections 674 and 674A of the Corporations Act; and
2. confirms that there is no information:
  - (a) that has been excluded from a continuous disclosure notice required to be given to ASX in accordance with the ASX Listing Rules; and
  - (b) that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
    - (i) the assets and liabilities, financial position and performance, profits and losses and prospects of Vioneering; and
    - (ii) the rights and liabilities attaching to the securities of Vioneering,to the extent to which it would be reasonable to investors and their professional advisers to expect to find such information in a disclosure document.

**Ends**

**This release was authorized by the CEO, Dr. Juan Carlos Aragón.**

For more information, please contact:

<b>Company</b>	<b>Investor and media relations</b>
Brian Lane COO and CFO, Visioneering Technologies, Inc. Email: <a href="mailto:blane@vtivision.com">blane@vtivision.com</a>	Haley Chartres H^CK Tel: +61 423 139 163 Email: <a href="mailto:haley@hck.digital">haley@hck.digital</a>

### About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in presbyopia and myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's flagship product is the NaturalVue® (etafilcon A) Enhanced Multifocal 1-Day Contact Lens, an extended depth of focus lens that the Company believes is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit [www.vtvision.com](http://www.vtvision.com) or call +1 844-884-5367, ext. 104.

### Foreign ownership restrictions

VTI's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers that are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.